| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain | 45 | 2020 | 949 | 4.050 |
Why?
|
| Mental Disorders | 11 | 2017 | 121 | 2.140 |
Why?
|
| Brain Injuries | 9 | 2015 | 93 | 1.640 |
Why?
|
| Magnetic Resonance Imaging | 27 | 2020 | 1323 | 1.590 |
Why?
|
| Brain Mapping | 15 | 2020 | 178 | 1.270 |
Why?
|
| Diagnostic Imaging | 7 | 2013 | 94 | 1.210 |
Why?
|
| Stress Disorders, Post-Traumatic | 5 | 2019 | 47 | 0.950 |
Why?
|
| Substance-Related Disorders | 5 | 2019 | 127 | 0.900 |
Why?
|
| Brain Diseases | 5 | 2016 | 38 | 0.880 |
Why?
|
| Humans | 79 | 2020 | 31836 | 0.840 |
Why?
|
| Animals | 20 | 2019 | 7450 | 0.570 |
Why?
|
| Stress, Psychological | 3 | 2020 | 218 | 0.570 |
Why?
|
| Fear | 2 | 2009 | 48 | 0.560 |
Why?
|
| Neuroanatomy | 3 | 2014 | 4 | 0.550 |
Why?
|
| Axons | 2 | 2007 | 34 | 0.520 |
Why?
|
| Psychiatry | 2 | 2008 | 19 | 0.500 |
Why?
|
| Solvents | 1 | 2015 | 4 | 0.500 |
Why?
|
| Image Processing, Computer-Assisted | 3 | 2015 | 227 | 0.500 |
Why?
|
| Veterans | 5 | 2017 | 66 | 0.480 |
Why?
|
| Positron-Emission Tomography | 7 | 2019 | 163 | 0.470 |
Why?
|
| Synapses | 1 | 2014 | 83 | 0.430 |
Why?
|
| Myelin Sheath | 2 | 2011 | 12 | 0.430 |
Why?
|
| Synaptic Transmission | 1 | 2014 | 116 | 0.430 |
Why?
|
| Aspartic Acid | 3 | 2017 | 12 | 0.430 |
Why?
|
| Emotions | 3 | 2011 | 56 | 0.420 |
Why?
|
| Toxoplasmosis, Cerebral | 1 | 2012 | 1 | 0.410 |
Why?
|
| Toxoplasma | 1 | 2012 | 2 | 0.410 |
Why?
|
| Occupational Exposure | 1 | 2015 | 233 | 0.400 |
Why?
|
| Reward | 1 | 2012 | 64 | 0.390 |
Why?
|
| Sleep | 2 | 2017 | 92 | 0.380 |
Why?
|
| Blast Injuries | 2 | 2015 | 25 | 0.380 |
Why?
|
| Myelinolysis, Central Pontine | 1 | 2011 | 1 | 0.380 |
Why?
|
| Neurons | 2 | 2014 | 409 | 0.370 |
Why?
|
| Neural Pathways | 3 | 2015 | 94 | 0.360 |
Why?
|
| Encephalitis, Herpes Simplex | 1 | 2010 | 2 | 0.350 |
Why?
|
| Astrocytes | 2 | 2008 | 58 | 0.350 |
Why?
|
| Brain Stem | 1 | 2010 | 20 | 0.350 |
Why?
|
| Dopamine | 1 | 2012 | 232 | 0.330 |
Why?
|
| Endocannabinoids | 1 | 2009 | 35 | 0.320 |
Why?
|
| Lyme Disease | 1 | 2008 | 1 | 0.310 |
Why?
|
| Mercury Poisoning, Nervous System | 1 | 2008 | 1 | 0.310 |
Why?
|
| Adaptation, Psychological | 2 | 2020 | 136 | 0.310 |
Why?
|
| Imaging, Three-Dimensional | 2 | 2006 | 132 | 0.300 |
Why?
|
| Diffuse Axonal Injury | 2 | 2006 | 3 | 0.300 |
Why?
|
| Anxiety | 1 | 2009 | 188 | 0.290 |
Why?
|
| Wit and Humor as Topic | 1 | 2007 | 1 | 0.290 |
Why?
|
| Delusions | 1 | 2007 | 3 | 0.290 |
Why?
|
| Cerebrovascular Circulation | 2 | 2005 | 92 | 0.290 |
Why?
|
| Magnetic Resonance Spectroscopy | 3 | 2010 | 82 | 0.280 |
Why?
|
| Psychotherapy | 2 | 2019 | 19 | 0.280 |
Why?
|
| Schizophrenia | 1 | 2007 | 31 | 0.280 |
Why?
|
| Cognition Disorders | 5 | 2015 | 384 | 0.270 |
Why?
|
| Panic | 1 | 2006 | 1 | 0.270 |
Why?
|
| Sleep Deprivation | 1 | 2006 | 9 | 0.270 |
Why?
|
| Explosions | 1 | 2006 | 12 | 0.270 |
Why?
|
| Tomography, Emission-Computed, Single-Photon | 3 | 2004 | 22 | 0.270 |
Why?
|
| Panic Disorder | 1 | 2006 | 4 | 0.270 |
Why?
|
| Neuropsychological Tests | 5 | 2015 | 370 | 0.260 |
Why?
|
| Dementia | 2 | 2006 | 251 | 0.260 |
Why?
|
| Image Enhancement | 1 | 2006 | 72 | 0.260 |
Why?
|
| Cerebral Cortex | 3 | 2014 | 125 | 0.260 |
Why?
|
| Rabies | 1 | 2005 | 1 | 0.250 |
Why?
|
| Histological Techniques | 1 | 2005 | 6 | 0.250 |
Why?
|
| Limbic System | 2 | 2006 | 13 | 0.250 |
Why?
|
| Cerebellum | 1 | 2005 | 26 | 0.250 |
Why?
|
| Epilepsy | 1 | 2006 | 82 | 0.240 |
Why?
|
| Military Personnel | 1 | 2006 | 87 | 0.240 |
Why?
|
| Prefrontal Cortex | 1 | 2005 | 70 | 0.240 |
Why?
|
| Amygdala | 1 | 2005 | 60 | 0.240 |
Why?
|
| Nerve Net | 2 | 2005 | 123 | 0.240 |
Why?
|
| Conversion Disorder | 1 | 2004 | 2 | 0.230 |
Why?
|
| Anxiety Disorders | 1 | 2005 | 77 | 0.230 |
Why?
|
| Diagnostic Techniques, Neurological | 1 | 2004 | 6 | 0.230 |
Why?
|
| Thalamus | 1 | 2004 | 33 | 0.230 |
Why?
|
| Leukodystrophy, Metachromatic | 1 | 2003 | 1 | 0.220 |
Why?
|
| AIDS Dementia Complex | 1 | 2003 | 2 | 0.220 |
Why?
|
| Choline | 3 | 2017 | 14 | 0.220 |
Why?
|
| Leukoencephalopathy, Progressive Multifocal | 1 | 2003 | 2 | 0.220 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2003 | 9 | 0.220 |
Why?
|
| Psychotic Disorders | 1 | 2003 | 11 | 0.220 |
Why?
|
| Tomography, Emission-Computed | 2 | 2003 | 23 | 0.220 |
Why?
|
| Creatine | 2 | 2017 | 5 | 0.210 |
Why?
|
| Borderline Personality Disorder | 2 | 2017 | 3 | 0.200 |
Why?
|
| Creutzfeldt-Jakob Syndrome | 1 | 2002 | 5 | 0.200 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2002 | 8 | 0.200 |
Why?
|
| Hallucinogens | 1 | 2002 | 12 | 0.200 |
Why?
|
| N-Methyl-3,4-methylenedioxyamphetamine | 1 | 2002 | 14 | 0.200 |
Why?
|
| Neurobiology | 2 | 2015 | 3 | 0.200 |
Why?
|
| Neurosciences | 1 | 2020 | 11 | 0.180 |
Why?
|
| Time Perception | 1 | 2020 | 8 | 0.180 |
Why?
|
| Behavior | 2 | 2013 | 30 | 0.170 |
Why?
|
| Combat Disorders | 1 | 2019 | 1 | 0.170 |
Why?
|
| Morals | 1 | 2019 | 4 | 0.170 |
Why?
|
| Electricity | 2 | 2009 | 2 | 0.170 |
Why?
|
| Fibromyalgia | 1 | 2019 | 25 | 0.160 |
Why?
|
| Self Concept | 1 | 2019 | 42 | 0.160 |
Why?
|
| Antipsychotic Agents | 2 | 2017 | 27 | 0.160 |
Why?
|
| Anger | 1 | 2018 | 4 | 0.160 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2010 | 912 | 0.160 |
Why?
|
| Essential Tremor | 1 | 2018 | 12 | 0.160 |
Why?
|
| Habenula | 1 | 2018 | 6 | 0.150 |
Why?
|
| Inositol | 1 | 2017 | 5 | 0.150 |
Why?
|
| Bupropion | 1 | 2017 | 5 | 0.150 |
Why?
|
| Adult | 7 | 2017 | 9327 | 0.150 |
Why?
|
| Hepatitis C, Chronic | 1 | 2017 | 77 | 0.140 |
Why?
|
| Depressive Disorder, Major | 1 | 2017 | 42 | 0.140 |
Why?
|
| Cognition | 3 | 2017 | 551 | 0.140 |
Why?
|
| Antidepressive Agents | 1 | 2017 | 74 | 0.140 |
Why?
|
| Pain | 1 | 2019 | 287 | 0.140 |
Why?
|
| Homeostasis | 1 | 2017 | 132 | 0.140 |
Why?
|
| Depression | 2 | 2018 | 442 | 0.130 |
Why?
|
| Pregnancy | 2 | 2011 | 994 | 0.130 |
Why?
|
| Wounds and Injuries | 2 | 2009 | 249 | 0.130 |
Why?
|
| Databases, Factual | 1 | 2017 | 349 | 0.130 |
Why?
|
| Alcoholism | 1 | 2017 | 101 | 0.130 |
Why?
|
| Chronic Disease | 2 | 2008 | 400 | 0.130 |
Why?
|
| Memory, Short-Term | 1 | 2016 | 60 | 0.130 |
Why?
|
| Sleep Apnea, Obstructive | 1 | 2016 | 58 | 0.130 |
Why?
|
| Colonic Pseudo-Obstruction | 1 | 2015 | 2 | 0.130 |
Why?
|
| Bipolar Disorder | 2 | 2006 | 16 | 0.130 |
Why?
|
| Stereotyping | 1 | 2015 | 8 | 0.130 |
Why?
|
| Young Adult | 3 | 2017 | 2603 | 0.130 |
Why?
|
| Models, Neurological | 1 | 2016 | 117 | 0.120 |
Why?
|
| Alzheimer Disease | 1 | 2019 | 327 | 0.120 |
Why?
|
| Heart Arrest | 1 | 2015 | 38 | 0.120 |
Why?
|
| Attention Deficit Disorder with Hyperactivity | 1 | 2015 | 36 | 0.120 |
Why?
|
| Epilepsy, Post-Traumatic | 1 | 2014 | 1 | 0.120 |
Why?
|
| Adolescent | 3 | 2017 | 3511 | 0.120 |
Why?
|
| Female | 10 | 2017 | 19859 | 0.110 |
Why?
|
| Child, Preschool | 2 | 2011 | 1259 | 0.110 |
Why?
|
| Neurotransmitter Agents | 2 | 2019 | 26 | 0.110 |
Why?
|
| Placebo Effect | 1 | 2013 | 14 | 0.110 |
Why?
|
| Stroke | 1 | 2018 | 581 | 0.110 |
Why?
|
| Patients | 1 | 2013 | 46 | 0.110 |
Why?
|
| Oxytocin | 1 | 2013 | 27 | 0.110 |
Why?
|
| Child | 2 | 2011 | 2425 | 0.110 |
Why?
|
| Recovery of Function | 1 | 2014 | 199 | 0.110 |
Why?
|
| Concept Formation | 1 | 2012 | 3 | 0.100 |
Why?
|
| Membrane Potentials | 2 | 2009 | 81 | 0.100 |
Why?
|
| Male | 8 | 2017 | 19091 | 0.100 |
Why?
|
| Cell Membrane | 2 | 2009 | 96 | 0.100 |
Why?
|
| Psychomotor Performance | 1 | 2012 | 99 | 0.100 |
Why?
|
| Adolescent Development | 1 | 2011 | 2 | 0.100 |
Why?
|
| Neuronal Plasticity | 1 | 2012 | 80 | 0.100 |
Why?
|
| Embryonic Development | 1 | 2011 | 7 | 0.100 |
Why?
|
| Gyrus Cinguli | 1 | 2011 | 22 | 0.090 |
Why?
|
| Fetal Development | 1 | 2011 | 25 | 0.090 |
Why?
|
| Radiographic Image Enhancement | 1 | 2010 | 26 | 0.090 |
Why?
|
| Child Development | 1 | 2011 | 43 | 0.090 |
Why?
|
| Treatment Outcome | 2 | 2013 | 3294 | 0.090 |
Why?
|
| Cranial Nerve Diseases | 1 | 2010 | 5 | 0.090 |
Why?
|
| Optics and Photonics | 1 | 2010 | 7 | 0.090 |
Why?
|
| Central Nervous System Diseases | 1 | 2010 | 13 | 0.090 |
Why?
|
| Syndrome | 1 | 2010 | 73 | 0.090 |
Why?
|
| Hallucinations | 2 | 2007 | 3 | 0.090 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 1 | 2010 | 53 | 0.090 |
Why?
|
| Sepsis | 1 | 2011 | 158 | 0.080 |
Why?
|
| Radionuclide Imaging | 2 | 2015 | 26 | 0.080 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2010 | 113 | 0.080 |
Why?
|
| Sex Characteristics | 1 | 2010 | 169 | 0.080 |
Why?
|
| Mood Disorders | 2 | 2006 | 21 | 0.080 |
Why?
|
| Infant, Newborn | 1 | 2011 | 665 | 0.080 |
Why?
|
| Receptor, Cannabinoid, CB1 | 1 | 2009 | 56 | 0.080 |
Why?
|
| Food Contamination | 1 | 2008 | 2 | 0.080 |
Why?
|
| Methylmercury Compounds | 1 | 2008 | 4 | 0.080 |
Why?
|
| Mercury | 1 | 2008 | 6 | 0.080 |
Why?
|
| Meat | 1 | 2008 | 15 | 0.080 |
Why?
|
| Fungicides, Industrial | 1 | 2008 | 9 | 0.080 |
Why?
|
| Prognosis | 2 | 2003 | 1498 | 0.080 |
Why?
|
| Drug Delivery Systems | 1 | 2009 | 104 | 0.080 |
Why?
|
| Fatal Outcome | 1 | 2008 | 81 | 0.080 |
Why?
|
| Alcoholic Intoxication | 1 | 2008 | 28 | 0.080 |
Why?
|
| Disease Progression | 1 | 2010 | 593 | 0.070 |
Why?
|
| Remission Induction | 2 | 2017 | 84 | 0.070 |
Why?
|
| Infant | 1 | 2011 | 1055 | 0.070 |
Why?
|
| Swine | 1 | 2008 | 215 | 0.070 |
Why?
|
| Laughter | 1 | 2007 | 3 | 0.070 |
Why?
|
| Transcranial Magnetic Stimulation | 1 | 2007 | 6 | 0.070 |
Why?
|
| Parietal Lobe | 1 | 2007 | 13 | 0.070 |
Why?
|
| Acute Disease | 1 | 2008 | 252 | 0.070 |
Why?
|
| Religion | 1 | 2007 | 32 | 0.070 |
Why?
|
| Time Factors | 2 | 2010 | 2146 | 0.070 |
Why?
|
| Cocaine-Related Disorders | 1 | 2008 | 99 | 0.070 |
Why?
|
| Sleep, REM | 1 | 2006 | 6 | 0.070 |
Why?
|
| Atmospheric Pressure | 1 | 2006 | 10 | 0.070 |
Why?
|
| Opioid-Related Disorders | 1 | 2007 | 54 | 0.070 |
Why?
|
| Arousal | 1 | 2006 | 19 | 0.070 |
Why?
|
| Regional Blood Flow | 1 | 2006 | 86 | 0.070 |
Why?
|
| Wakefulness | 1 | 2006 | 25 | 0.070 |
Why?
|
| Temporal Lobe | 1 | 2006 | 30 | 0.070 |
Why?
|
| Circadian Rhythm | 1 | 2006 | 43 | 0.070 |
Why?
|
| Pseudobulbar Palsy | 1 | 2005 | 5 | 0.060 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 518 | 0.060 |
Why?
|
| Oxygen Consumption | 1 | 2006 | 152 | 0.060 |
Why?
|
| Phobic Disorders | 1 | 2005 | 9 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2005 | 59 | 0.060 |
Why?
|
| History, 20th Century | 1 | 2005 | 71 | 0.060 |
Why?
|
| Brain Concussion | 1 | 2005 | 62 | 0.060 |
Why?
|
| Electroencephalography | 3 | 2011 | 72 | 0.060 |
Why?
|
| Glasgow Coma Scale | 1 | 2004 | 27 | 0.060 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 2004 | 11 | 0.060 |
Why?
|
| Basal Ganglia | 1 | 2004 | 15 | 0.060 |
Why?
|
| S100 Proteins | 1 | 2004 | 18 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2004 | 45 | 0.060 |
Why?
|
| Neurodegenerative Diseases | 1 | 2004 | 13 | 0.060 |
Why?
|
| Case-Control Studies | 2 | 2017 | 895 | 0.060 |
Why?
|
| Athletic Injuries | 1 | 2005 | 82 | 0.060 |
Why?
|
| Cerebrovascular Disorders | 1 | 2004 | 51 | 0.060 |
Why?
|
| Inclusion Bodies, Viral | 1 | 2003 | 4 | 0.050 |
Why?
|
| Oligodendroglia | 1 | 2003 | 3 | 0.050 |
Why?
|
| Virus Activation | 1 | 2003 | 7 | 0.050 |
Why?
|
| Oxygen | 1 | 2004 | 140 | 0.050 |
Why?
|
| Hemoglobins | 1 | 2003 | 47 | 0.050 |
Why?
|
| Multiple Sclerosis | 1 | 2004 | 59 | 0.050 |
Why?
|
| Reference Values | 1 | 2003 | 247 | 0.050 |
Why?
|
| Oximes | 1 | 2002 | 6 | 0.050 |
Why?
|
| Globus Pallidus | 1 | 2002 | 8 | 0.050 |
Why?
|
| Nerve Degeneration | 1 | 2002 | 14 | 0.050 |
Why?
|
| Serotonin | 1 | 2002 | 37 | 0.050 |
Why?
|
| Vasoconstriction | 1 | 2002 | 41 | 0.050 |
Why?
|
| Frontal Lobe | 1 | 2002 | 36 | 0.050 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2002 | 50 | 0.050 |
Why?
|
| Corpus Striatum | 1 | 2002 | 60 | 0.050 |
Why?
|
| Radiopharmaceuticals | 1 | 2002 | 90 | 0.050 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 2 | 2011 | 30 | 0.050 |
Why?
|
| Meta-Analysis as Topic | 1 | 2020 | 43 | 0.040 |
Why?
|
| Ultrasonography | 1 | 2003 | 378 | 0.040 |
Why?
|
| Middle Aged | 4 | 2017 | 11824 | 0.040 |
Why?
|
| Risk Factors | 2 | 2019 | 3851 | 0.040 |
Why?
|
| United States | 2 | 2017 | 3925 | 0.040 |
Why?
|
| Isoquinolines | 1 | 2017 | 7 | 0.040 |
Why?
|
| Radioligand Assay | 1 | 2017 | 20 | 0.040 |
Why?
|
| Afghan Campaign 2001- | 1 | 2017 | 14 | 0.040 |
Why?
|
| Drug Synergism | 1 | 2017 | 66 | 0.040 |
Why?
|
| Drug Resistance | 1 | 2017 | 39 | 0.040 |
Why?
|
| Follow-Up Studies | 1 | 2003 | 2271 | 0.040 |
Why?
|
| Microglia | 1 | 2017 | 57 | 0.040 |
Why?
|
| United States Department of Veterans Affairs | 1 | 2017 | 62 | 0.040 |
Why?
|
| Drug Therapy, Combination | 1 | 2017 | 284 | 0.030 |
Why?
|
| Diffusion Tensor Imaging | 1 | 2015 | 28 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2017 | 504 | 0.030 |
Why?
|
| Retrospective Studies | 1 | 2002 | 3488 | 0.030 |
Why?
|
| Risk | 1 | 2014 | 318 | 0.030 |
Why?
|
| Administration, Intranasal | 1 | 2013 | 31 | 0.030 |
Why?
|
| Haplorhini | 1 | 2013 | 66 | 0.030 |
Why?
|
| Parasympathetic Nervous System | 1 | 2011 | 2 | 0.020 |
Why?
|
| Radiographic Image Interpretation, Computer-Assisted | 1 | 2010 | 38 | 0.020 |
Why?
|
| Injury Severity Score | 1 | 2010 | 111 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2011 | 109 | 0.020 |
Why?
|
| Disease Susceptibility | 1 | 2010 | 57 | 0.020 |
Why?
|
| Sensitivity and Specificity | 1 | 2010 | 589 | 0.020 |
Why?
|
| Quality of Life | 1 | 2015 | 924 | 0.020 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 404 | 0.020 |
Why?
|
| Oligoclonal Bands | 1 | 2004 | 2 | 0.010 |
Why?
|
| Aged | 1 | 2017 | 10288 | 0.010 |
Why?
|
| Compulsive Personality Disorder | 1 | 2003 | 1 | 0.010 |
Why?
|
| Fenfluramine | 1 | 2003 | 4 | 0.010 |
Why?
|
| Serotonin Agents | 1 | 2003 | 5 | 0.010 |
Why?
|
| Tryptophan | 1 | 2003 | 4 | 0.010 |
Why?
|
| Mass Screening | 1 | 2005 | 263 | 0.010 |
Why?
|
| Creatinine | 1 | 2003 | 195 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2004 | 899 | 0.010 |
Why?
|